Carson 3rd Qtr revenues will be irrelevant at this point,

New Post Public Reply Private Reply Replies (2) Message Board
CyberJ Carson #888
552
Carson 3rd Qtr revenues will be irrelevant at this point, as it relates to anything future

Some details will give some insight into shares warrants,

Gary knows the 3rd Qtr results, rumor has it, the expectation might be lower than some of your figures or the 1.5 mil I expected, some have rumored it to be around 900 K That could be because a client didn't pay a significant payment on time. Gary counts revenues money received on time, that money wasn't received by end of September will count in October I am told. But it doesn't matter now as Gary is expecting a huge 4th Qtr. Maverick will be paying on the 4th Qtr so will the UK and other accounts. Maybe the 4th Qtr will be bogger than 4 mill maybe 5 million or more.

That 900 k ballpark figure or thereabouts might make investors draw wrong conclusions on the 4th Qtr being less than the 4 million Gary earlier projected, now some bashers might attempt to convince others that PCTL is in someway into a downward trend.


Perhaps Gary wanted to head off any misleading interpretations because the revenue that might be a little less than expected from the 3rd Qtr, by stating the expectation for the 4th Qtr of 2020 remains unchanged, reiterating the figure of 4 million-plus.

3rd Qtr meaningless. Also, forward-looking statements will outline current new deals and updates on orders etc. He could also give an update on October's revenues.

Gary would know what revenues are coming in. He is NOT a pumper.

Look at the deals we just learned of. Based on the deals we were just made aware of Gary went further than 4 million in 2020 he made early a revenue guidance for 2021 of 10 million.

That's not a stretch either as we learned he signed the Maverick deal that is worth multi-millions could be 4 to 5 million on its own merit. Doesn't include the UK, but those UK revenues will impact 2020 4th Qtr and there is no doubt 2021 revenues will be impacted significantly.
PCTL all the way to the moon~~ !!

PCT Ltd. (PCTL) Stock Research Links

PCTL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 19

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 24

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 30

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 18

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 23

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 25

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Alterity Therapeutics Showcases Innovation at Healthcare Event

Updated Category News Views 142

Alterity Therapeutics to Present at a Virtual Healthcare Conference Alterity Therapeutics, a biotechnology firm dedicated to developing treatments for neurodegenerative diseases, has recently announced its participation in an upcoming healthcare virtual conference. The event will shine a spotlight on influential healthcare companies and their innovative approaches to...

Continue Reading
Important Update for Toronto-Dominion Bank Investors on Lawsuit

Updated Category News Views 58

Update for Investors in Toronto-Dominion Bank Kahn Swick & Foti, LLC, led by the experienced former Louisiana Attorney General Charles C. Foti, Jr., is reminding investors that significant changes are arriving for shareholders of Toronto-Dominion Bank (NYSE: TD). As the legal landscape evolves, those who experienced losses may want to take immediate action regarding their...

Continue Reading
GCC's Quarterly Performance Analysis: Key Insights Revealed

Updated Category News Views 221

GCC Reports Significant First Quarter Financials GCC, S.A.B. de C.V. (BMV: GCC*), recognized as a premier supplier and producer of cement, concrete, and aggregates, has shared its financial results for the first quarter. Despite facing various challenges, GCC's performance metrics reveal a resilience that is noteworthy. Q1 2025 Highlights In the first quarter of 2025, GCC...

Continue Reading
Indonesia's IDX Composite Index Declines Amid Market Pressures

Updated Category News Views 116

Overview of Recent Market Movements in Indonesia Indonesia's stock market experienced a downturn at the close of trading, influenced by various sectors showing significant losses. The IDX Composite Index reflected a decrease of 0.98%, marking a notable dip to a one-month low. This downturn is primarily attributed to declines in several key sectors, including...

Continue Reading
Blink Charging Achieves Advanced Certification for EV Chargers

Updated Category News Views 130

Blink Charging Receives Prestigious OCPP 2.0.1 Certification Blink stands out as one of just five EV charging companies in the U.S. to earn this coveted certification. Bowie, Md. – Blink Charging Co. (NASDAQ: BLNK), a prominent name in electric vehicle (EV) charging equipment and services, has proudly announced that its Series 7, 8, and 9 charger models have...

Continue Reading